International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network

Circulation

Abstract

Unstable angina and non-Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation. At 273 hospitals in 20 countries, 2282 patients were randomly assigned to lamifiban (2x2 factorial design: low-dose [1 microg/min] with and without heparin versus high-dose [5 microg/min] with and without heparin) or to standard therapy (placebo and heparin). All patients received aspirin. The composite primary end point of death or nonfatal myocardial infarction at 30 days occurred in 11.7% of those receiving standard therapy, 10.6% receiving low-dose lamifiban, and 12.0% receiving high-dose lamifiban (P=0.668). By 6 months, this composite was lowest for those assigned to low-dose lamifiban (P=0.027) and intermediate for those assigned to high-dose lamifiban (P=0.450) compared with control (13.7%, 16.4%, and 17.9%, respectively). Compared with control, the combination of high-dose lamifiban and heparin resulted in more intermediate or major bleeding (12...Continue Reading

References

Jul 16, 1992·The New England Journal of Medicine·J E WillardL D Hillis
Nov 11, 1992·Journal of the American College of Cardiology·R S SchwartzE J Topol
Oct 27, 1988·The New England Journal of Medicine·P ThérouxP deGuise
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
Sep 12, 1996·The New England Journal of Medicine·UNKNOWN Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
Feb 12, 1997·JAMA : the Journal of the American Medical Association·T Q KongR O Bonow
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators

❮ Previous
Next ❯

Citations

Sep 24, 1999·Clinical Cardiology·J T Willerson, P Zoldhelyi
Apr 13, 2001·Medicinal Research Reviews·N S NicholsonR J Anders
Sep 1, 2005·Der Anaesthesist·J-H SchiffB W Böttiger
Sep 28, 2005·Cardiovascular Drugs and Therapy·Matthias BramkampThomas D Szucs
Aug 18, 2010·Cardiovascular Drugs and Therapy·Nicolas Danchin, Nadia Aïssaoui
Jan 16, 2007·Journal of Thrombosis and Thrombolysis·Jonathan D RichChristopher P Cannon
Mar 20, 2001·Current Atherosclerosis Reports·P Nguyen-Ho, N M Lakkis
Jun 8, 2002·Current Cardiology Reports·Henock Saint-Jacques, And Robert A Harrington
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·M B Murad, T D Henry
Mar 5, 2004·International Journal of Cardiology·E Ercan
Oct 18, 2003·American Heart Journal·Thao HuynhUNKNOWN Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca
Nov 6, 2001·The American Journal of Cardiology·D D Waters
Jul 16, 2003·The American Journal of Cardiology·Deepak L BhattUNKNOWN PURSUIT Investigators
Sep 7, 2000·The American Journal of Medicine·M S Sabatine, I K Jang
Sep 18, 1999·Thrombosis Research·R GalloJ J Badimon
May 5, 1999·Lancet·J Hirsh, J I Weitz
Jun 22, 1999·Lancet·F W Verheugt
Dec 18, 2001·International Journal of Cardiology·A R HoughtonI Hudson
May 18, 1999·International Journal of Cardiology·M FerrarioD Ardissino
Jan 26, 2000·International Journal of Cardiology·R D Bahr
Apr 12, 2000·Journal of the American College of Cardiology·A M LincoffE J Topol
Jul 14, 2001·Journal of the American College of Cardiology·P KaulUNKNOWN PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network
Feb 7, 2003·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
Mar 20, 2003·Journal of the American College of Cardiology·David J Moliterno, Albert W Chan
Mar 16, 2000·British Journal of Clinical Pharmacology·B WittkeS J Machin
Aug 15, 1998·The New England Journal of Medicine·UNKNOWN Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigato
Oct 17, 1998·The New England Journal of Medicine·M Liron
Jan 13, 2000·The New England Journal of Medicine·Y YeghiazariansP H Stone
Sep 1, 1999·Current Opinion in Hematology·M MadanS D Berkowitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Related Papers

The New England Journal of Medicine
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
The New England Journal of Medicine
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
The New England Journal of Medicine
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigato
© 2022 Meta ULC. All rights reserved